Combined epicardial substrate ablation of the right ventricular outflow tract and implantation of an epicardial ICD was reported as feasible and safe in a 3-year-old boy with Brugada syndrome.
Case Report (n=1)
Is combined epicardial substrate ablation of the RVOT and epicardial ICD implantation feasible and safe in a 3-year-old boy with highly symptomatic Brugada syndrome?
Combined epicardial RVOT ablation and epicardial ICD implantation may be a feasible and safe approach for managing highly symptomatic Brugada syndrome in very young pediatric patients.
Brugada syndrome (BrS) is a primary electrical disease of autosomal dominant inheritance, characterized by coved-type ST-segment elevation in the right precordial leads and increased risk of sudden cardiac death.1 Although the initial description included 3 children in a series of 8 patients,2 the prevalence of BrS in pediatric populations was extremely low (0.0098%) in subsequent studies compared to adults in the fourth or fifth decade of life (range 0.14%–0.7%).3 We report the case of a 3-year-old boy with highly symptomatic BrS, focusing on the feasibility and safety of combined epicardial substrate ablation of the right ventricular outflow tract (RVOT) and implantation of an epicardial implantable cardioverter-defibrillator (ICD).
Asmundis et al. (Sun,) conducted a case report in Brugada syndrome (n=1). Combined epicardial substrate ablation of the right ventricular outflow tract and implantation of an epicardial ICD was evaluated on Feasibility and safety. Combined epicardial substrate ablation of the right ventricular outflow tract and implantation of an epicardial ICD was reported as feasible and safe in a 3-year-old boy with Brugada syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: